Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEREIDA: plitidepsin versus control in hospitalized immunocompromised adults with symptomatic COVID-19
MOH_2023-07-23_012791Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Jul 2023
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of plitidepsin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by PharmaMar. Started Jul 2023; status: completed.
02
Drugs
plitidepsin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2023-07-23_012791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-23_012791.